ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Aptose Biosciences Inc

Aptose Biosciences Inc (APS)

0,345
0,005
( 1,47% )
Mis à jour : 18:02:26

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

Dernier
0,345
Prix Achat
0,34
Prix Vente
0,36
Volume échangé
27 500
0,32 Fourchette du Jour 0,355
0,19 Plage de 52 semaines 3,48
Clôture Veille
0,34
Ouverture
0,355
Dernière Transaction
500
@
0.345
Dernière heure de transaction
18:02:25
Volume moyen (3 m)
34 113
Volume financier
-
VWAP
-

APS Dernières nouvelles

Aptose Announces Positive Decision by Nasdaq Hearings Panel

SAN DIEGO and TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing...

Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax

Peer-reviewed publication details unique TUS mechanism of action TUS+VEN combination synthetic lethality overcomes resistance to VEN Tuspetinib prolongs survival in multiple AML models resistant...

Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML

TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling at U.S. SitesTUS and TUS+VEN Broadly Active Across AML Populations, with Favorable SafetyTUS-based therapies are...

Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials

Tuspetinib selected for a prestigious national clinical research program for ability to target broad spectrum of AML and MDS populations Trials to test tuspetinib in targeted drug combinations for...

Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering

SAN DIEGO and TORONTO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing...

Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering

SAN DIEGO and TORONTO, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing...

Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy

TUSCANY study is open to enroll patients to receive TUS+VEN+AZA triplet at select US sitesFavorable safety and broad clinical activity make tuspetinib an ideal agent to combine with venetoclax and...

Aptose Reports Results for the Third Quarter 2024

SAN DIEGO and TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing...

Aptose Announces Results from Special Meeting of Shareholders

SAN DIEGO and TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing...

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib

SAN DIEGO and TORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.035-9.210526315790.380.440.3877200.35177839CS
40.140.81632653060.2450.550.24557220.35349939CS
12-0.165-32.35294117650.510.580.19341130.34811295CS
26-0.675-66.17647058821.021.10.19200670.4304819CS
52-2.895-89.35185185193.243.480.19139690.89641609CS
156-26.505-98.715083798926.8529.250.191698812.92986164CS
260-103.605-99.6681096681103.95189.30.193464876.28076741CS

APS - Frequently Asked Questions (FAQ)

What is the current Aptose Biosciences share price?
The current share price of Aptose Biosciences is $ 0,345
What is the 1 year trading range for Aptose Biosciences share price?
Aptose Biosciences has traded in the range of $ 0,19 to $ 3,48 during the past year

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
VRTSVertiqal Studios Corporation
$ 0,02
(33,33%)
590,11k
GRCGold Springs Resource Corp
$ 0,07
(16,67%)
3k
ARAAclara Resources Inc
$ 0,53
(16,48%)
96k
BSXBelo Sun Mining Corp
$ 0,05
(11,11%)
1,11M
KRNKarnalyte Resources Inc
$ 0,105
(10,53%)
5k
BABYElse Nutrition Holdings Inc
$ 0,015
(-25,00%)
512,75k
RTGRTG Mining Inc
$ 0,03
(-25,00%)
38,42k
IVQInvesque Inc
$ 0,11
(-12,00%)
73k
CJR.BCorus Entertainment Inc
$ 0,075
(-11,76%)
1,18M
TWMTidewater Midstream and Infrastructure Ltd
$ 0,115
(-11,54%)
1,71M
TTelus Corp
$ 19,23
(-1,18%)
3,22M
BTEBaytex Energy Corp
$ 3,52
(1,15%)
2,41M
BCEBCE Inc
$ 32,16
(-1,50%)
2,05M
WNDRWonderFi Technologies Inc
$ 0,27
(-5,26%)
1,97M
TWMTidewater Midstream and Infrastructure Ltd
$ 0,115
(-11,54%)
1,71M
Aucune Discussion Trouvée
Ajouter une Discussion